The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma
- 37 Downloads
Definitive chemoradiotherapy (CRT), used for treatment of patients with an initial diagnosis of unresectable locally advanced esophageal cancer, has led to unsatisfactory long-term prognosis. Moreover, CRT can lead to esophageal fistula, perforation, and strictures. Therefore, strong induction chemotherapeutic treatments are necessary to reduce the tumor volume for subsequent radical esophagectomy. This study aimed to determine the oncological utility of docetaxel plus cisplatin and 5-fluorouracil (DCF) and the technical feasibility of subsequent esophagectomy for locally advanced esophageal cancer.
Eighty-seven patients with clinical borderline unresectable T3 and T4 esophageal squamous cell carcinoma without distant metastases were included in this study. There were 44 patients in primary DCF group and 43 patients in definitive CRT group, and perioperative and long-term oncological outcomes were compared between the two groups.
Twenty-two patients (50%) achieved R0 resection in the DCF group. Albeit not significant, the rate of curative treatment was higher in the DCF group than the definitive CRT group (p = 0.099). The overall survival (OS) and progression-free survival (PFS) were better with DCF than with definitive CRT (median OS, 29 vs. 17 months, p = 0.206; median PFS, 10 vs. 6 months, p = 0.020). Specifically, the OS of patients with a Charlson score of less than 3 among the DCF-treated patients tended to be better than those among the definitive CRT-treated patients.
DCF and subsequent esophagectomy achieved R0 resection in 50% of the patients and was associated with better long-term oncological outcomes in patients with initially unresectable esophageal cancer if their systemic status is acceptable.
The authors thank Kumiko Motooka in the Department of Surgery at Keio University School of Medicine for her help in the preparation of the manuscript.
Compliance with ethical standards
Conflict of interest
Yuko Kitagawa have personal fees from sanofi K.K, personal fees from ETHICON PART OF JOHNSON AND JOHNSON FAMILY OF COMPANIES, personal fees from Medtronic Japan Co., Ltd., grants from KYOWA HAKKO KIRIN CO., LTD, outside the submitted work.
- 8.Okuno T, Wakabayashi M, Kato K et al (2017) Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). Int J Clin Oncol 22:1042–1049CrossRefGoogle Scholar
- 13.Japanese Classification of Esophageal Cancer (2016) 11th Edition: part I. Esophagus 14:1–36Google Scholar
- 15.Sobin L, Gospodarowicz MWC (eds) (2009) TNM classification of malignant tumours, 7th edn. Wiley-Liss, New YorkGoogle Scholar
- 19.Yokota T, Hatooka S, Ura T et al (2011) Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res 31:3535–3541Google Scholar
- 24.Poon LC, Wright D, Rolnik DL et al (2017) Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol 217:585e1–585e5CrossRefGoogle Scholar
- 25.Satake H, Tahara M, Mochizuki S et al (2016) A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol 78:91–99CrossRefGoogle Scholar
- 27.Makino T, Yamasaki M, Miyazaki Y et al (2017) Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus 31:dox130Google Scholar